ArticleFrontiers in chemistry2021
Quercetin Rejuvenates Sensitization of Colistin-Resistant
Article in Frontiers in chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Natural compounds: a promising therapeutic option for managing colistin-resistant bacteria and improving colistin activity.Molecular biology reports · 2026Review
- PFK-158 enhances colistin efficacy against resistantFrontiers in veterinary science · 2026Article
- Dual action of herbal compounds inFrontiers in immunology · 2026Review
- Quercetin Enhances the Antibacterial Activity of Polymyxin E Against MCR-1-Positive Bacteria by Inhibiting the Biological Functions of the Cell Membrane.Animals : an open access journal from MDPI · 2025Article
- Advances and mechanisms of traditional Chinese medicine and its active ingredients against antibiotic-resistantJournal of pharmaceutical analysis · 2025Review
- Multi-target mechanisms and potential applications of quercetin in the treatment of acne vulgaris.Frontiers in pharmacology · 2025Review
- Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistantFrontiers in microbiology · 2025Article
- Kaempferol restores the susceptibility of ESBLsFrontiers in microbiology · 2024Article
- Combination of aloe emodin, emodin, and rhein from Aloe with EDTA sensitizes the resistantFrontiers in cellular and infection microbiology · 2024Article
- Dynamic covalent nano-networks comprising antibiotics and polyphenols orchestrate bacterial drug resistance reversal and inflammation alleviation.Bioactive materials · 2023Article
- Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-ResistantAntimicrobial agents and chemotherapy · 2023Article
- Thymol-Decorated Gold Nanoparticles for Curing Clinical Infections Caused by Bacteria Resistant to Last-Resort Antibiotics.mSphere · 2023Article
- Quercetin: Synergistic Interaction with Antibiotics against Colistin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- The Antibacterial Activity of Kaempferol Combined with Colistin against Colistin-Resistant Gram-Negative Bacteria.Microbiology spectrum · 2022Article
- Thymol Increases Sensitivity of Clinical Col-R Gram-Negative Bacteria to Colistin.Microbiology spectrum · 2022Article
- Naringenin restores colistin activation against colistin-resistant gram-negative bacteriaFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin is being considered as "the last ditch" treatment in many infections caused by Gram-negative stains. However, colistin is becoming increasingly invalid in treating patients who are infected with colistin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.